Publication | Closed Access

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

Phase 1BHematological MalignancyAzacitidine Versus AzacitidineMedicineMixed-phenotype Acute LeukemiaHematologyPathologyPharmacotherapyOncologyCancer ResearchMyeloid Neoplasia